Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Trial details
- Registry ID
- NCT02492711
- Drugs studied
- Margetuximab, Physician's choice of chemotherapy., Trastuzumab
TrialRedline tracks 10 clinical trials sponsored by MacroGenics: 2 Phase 3, 2 Phase 2 / 3, 6 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 | Margetuximab, Physician's choice of chemotherapy., Trastuzumab | Completed | 2021-08-11Actual |
| Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00920582 | Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen, Teplizumab Herold Regimen | Terminated | 2012-04Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364 | Chemotherapy, Retifanlimab, Tebotelimab, Trastuzumab and 1 more | Completed | 2024-01-15Actual |
| The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697 | Teplizumab | Completed | 2010-06Actual |
Names as written in the registry records.
NCT06730347 · MacroGenics
Before: 60 participants (planned). After: 80 participants (planned).
Before: Feb 2027. After: Jul 2027.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: Sep 2026. After: 19 Feb 2026.